Iaso Ventures focuses on catalyzing biodigital innovation in the life sciences sector. The company invests in startups that aim to cure diseases and improve patient lives, utilizing data-driven technologies and platforms for therapeutic development.

Iaso Ventures

Iaso Ventures | 720 followers on LinkedIn. Early-stage investment and venture-building firm focused on neuroscience | Iaso Ventures is a venture capital firm located in Boston. Our investor-operator team and strategic partner network is passionate about helping early-stage ventures succeed and move the needle in the brain health sector.

Digital Health Strategist & Researcher | Mental Health Advocate & Educator | Change Leadership Trainer, Facilitator and Coach

Craig A. DeLarge, MPH, MBA, CPC

Venture investor, Harvard professor, entrepreneur

Wasim Malik

Founder at Latent Strategies

John Reynders

Life Science Entrepreneur & Investor

Jeff Carter

Thrilled to share that the New York Stock Exchange celebrated our Series A financing on the trading floor after yesterday’s opening bell. Thanks, NYSE for the recognition!

Axonis Therapeutics

We are delighted to announce the latest investment from the Iaso NeuroImpact Fund in Axonis Therapeutics

Prudentia is #hiring a new Senior Data Scientist!

Prudentia Sciences

🚀 Innovation through Simplicity 🚀 At Pragma Bio, we believe that the most groundbreaking discoveries often come from stripping away the complexities and focusing on the core essence—much like Picasso did with his famous series, “The Bull.” 🐂 His journey from detailed depictions to just a few elegant lines teaches us a powerful lesson: true mastery lies in understanding and simplifying the fundamentals. Today, we’re excited to share how we’ve applied this philosophy to our PIKASO platform, which is transforming the way we discover and develop small molecules. By learning from nature’s own evolutionary refinement, we’re pioneering a new approach in the biotech space that links animal health with human therapeutics. It’s a testament to the power of being open-minded, creative, and inspired by other fields to fuel innovation in our own. Our latest article dives deep into how PIKASO enables us to cut through the complexity of drug discovery, making it faster and more efficient. I invite you to read the full piece and explore how we’re turning the art of microbiology into actionable chemistry. Let’s keep pushing the boundaries and continue learning from every discipline around us. The intersection of science, art, and technology is where true innovation happens. 🔗 https://lnkd.in/gJWrj3D6 #Biotech #Innovation #DrugDiscovery #PragmaBio #PIKASO #Healthcare #Simplicity

Kareem Barghouti

🚀 Exciting News! Ryght has joined the prestigious CancerX Program to accelerate innovation in cancer research! 🌟 We are proud to announce our partnership with CancerX, a groundbreaking public-private initiative aimed at driving innovation in the fight against cancer. CancerX, launched as part of the White House’s Cancer Moonshot, brings together leaders in oncology and digital health to set priorities and practices for harnessing the full power of innovation. Chadi Nabhan, MD, MBA,FACP our Chief Medical Officer and Head of Strategy, states, "By collaborating with CancerX, we can accelerate the adoption of AI-driven innovations that drive clinical research and make a positive impact on the way cancer care is delivered for all patients everywhere." Together, we're working to enhance clinical research, improve outcomes, and make a real difference in the lives of cancer patients. 🌐 Read more: https://hubs.li/Q02GXsGP0 #CancerX #Innovation #CancerResearch #GenAI #ClinicalTrials #Ryght #HealthcareTechnology

Ryght

Great clinical study data on seizure monitoring technology from EpiWatch , an Iaso NeuroImpact Fund portfolio company

We are delighted to support BioCentury Inc. Grand Rounds.

Thrilled to announce our Seed Extension has completed with an oversubscribed round that lets our team accomplish even more incredible milestones at CatenaBio

Marco Lobba, Ph.D.

Exciting news! 🎉 Today, we are proud to announce the public availability of Ryght Preview, a significant advancement in the application of generative AI ( #GenAI ) within the #healthcare and #lifesciences industries. We’re building a platform to optimize #clinicalresearch and operational efficiency through an evolving range of customized #copilots designed to support the entire clinical trial continuum. Our bigger vision is to facilitate interaction among key stakeholders, smoother operations, and improved collaboration that results in faster introduction of drugs to market and better patient outcomes. Stay tuned for more to come.. Ryght Preview is now available for free to life sciences knowledge workers. For those interested in further customization or exploring additional features, contact our team to discuss the full capabilities of Ryght for Enterprise. Sign up now for Ryght Preview at the link in comments to start working smarter. Read the full press release below 👉 https://hubs.li/Q02t0bq80 #lifesciences #CRO #clinicaltrials #healthcare

Excited to be in sunny San Diego for #AACR24 . We'll be presenting CatenaBio 's latest breaking data on our #MPC technology including exciting updates on our in vivo trial. Swing by our poster on Tuesday, Section 22 poster 6! (Abstract 5797 if you miss us!) American Association for Cancer Research Come find me or Rick Kendall or Saurabh Johri . Great to see some of our partners already Farnaz B. Stephen Curtis from American Cancer Society

Metric
Company Name	Iaso Ventures
Symbol
MSH ID	COM:IASOVENTURES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Venture Capital
Country	US
Stage
Employee Count
Website	iasoventures.com
LinkedIn	iasoventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	776
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

IASO

COM:IASOVENTURES

Iaso Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue